Octreotide-LAR

DRUG4 trials

Sponsors

Federico II University, Mario Negri Institute for Pharmacological Research

Conditions

AcromegalyAutosomal Dominant Polycystic Kidney DiseaseGastrointestinal NeoplasmsMultiple Endocrine NeoplasiaPancreatic NeoplasmsRespiratory Tract NeoplasmsThymic Neoplasms

Phase 2

High Dose Somatostatin Analogues in Neuroendocrine Tumors

CompletedNCT00990535

Federico II UniversityGastrointestinal Neoplasms, Multiple Endocrine Neoplasia, Pancreatic Neoplasms +2

Start: 2006-01-31End: 2008-12-31Updated: 2009-10-07

Phase 3

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

CompletedNCT01377246

Mario Negri Institute for Pharmacological ResearchAutosomal Dominant Polycystic Kidney Disease

Start: 2011-05-31End: 2017-10-18Updated: 2018-01-10

Phase 4

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

CompletedNCT00461149

Federico II UniversityAcromegaly

Start: 1995-01-31End: 2006-12-31Target: 50Updated: 2007-04-17

Unknown Phase

Prediction of Tumor Shrinkage in Acromegaly

CompletedNCT00616408

Federico II UniversityAcromegaly

Start: 1997-01-31End: 2007-12-31Updated: 2008-02-15

Related Papers

Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial

PLoS Medicine2019-04-0573 citations